Since the FDA approved semaglutide for weight loss in 2021, calls to U.S. poison centers about GLP-1 receptor agonist exposures have spiked sharply. A new study found semaglutide now dominates reported cases, with more young women affected and more patients needing medical care. Researchers say better public education on these drugs is urgently needed.
When the FDA approved semaglutide for weight loss in July 2021, it opened the floodgates — not just for prescriptions, but also for poison center calls. A new study in the Journal of Medical Toxicology analyzed over 10,000 GLP-1 receptor agonist (GLP-1 RA) exposure reports to the National Poison Data System from 2012 to 2023, finding a dramatic uptick after the FDA's weight loss approval.
Semaglutide quickly became the dominant drug in reported cases post-approval, and the exposed population shifted toward younger individuals and more females. Most incidents were unintentional therapeutic errors, typically causing mild GI symptoms — but the share of cases requiring medical facility care rose notably.
By the Numbers:
Why it matters: As GLP-1 drugs shift from diabetes management to mainstream weight loss tools, the risk profile changes significantly. Researchers are calling for stronger public education, noting that the drug's behavior in the body and its long-term safety are still not fully understood.
